What pregnancy safety data exists for Taltz (ixekizumab)?
Taltz (ixekizumab) is an IL‑17A inhibitor, and questions about pregnancy safety usually focus on whether exposure increases risks of miscarriage, birth defects, or impaired growth. Based on the available labeling information for Taltz, ixekizumab is not known to be a major teratogenic risk, but pregnancy data are still limited because biologics are studied in fewer pregnancies than older, small-molecule drugs. This means clinicians typically weigh the benefit of controlling the mother’s disease against any potential fetal risks.
Does Taltz increase miscarriage or birth defect risk?
The main concern for patients is whether Taltz use during pregnancy raises the risk of birth defects or miscarriage. Current pregnancy experience with Taltz has not shown a clear signal of increased major birth defects, but the certainty is limited by the number of exposed pregnancies and the observational nature of much of the data. If you are pregnant (or trying to conceive), your prescriber may recommend continuing treatment if stopping could lead to uncontrolled disease activity, since that can also pose risks during pregnancy.
Should you stop Taltz during pregnancy, or continue?
Whether to continue depends on the reason Taltz was prescribed (for example, psoriatic disease) and how well symptoms are controlled. Stopping a biologic can lead to flare-ups, and poorly controlled inflammatory conditions can adversely affect pregnancy outcomes. For that reason, decisions are individualized: clinicians often consider disease severity, prior flare history, and gestational timing when discussing treatment.
Can you use Taltz while trying to get pregnant or during the first trimester?
Many patients ask specifically about early pregnancy because this is when the risk of structural birth defects is highest. For Taltz, there is no established recommendation that it must be avoided in early pregnancy, but decisions still rely on risk–benefit discussions due to limited pregnancy exposure data.
What about breastfeeding after delivery?
A common follow-up is whether Taltz is safe during breastfeeding. The breastfeeding question is usually handled similarly: check the drug label for guidance and weigh the benefits of maternal disease control against the theoretical risk of drug transfer into milk. Your clinician can help you decide based on your situation.
Are there alternatives if you’re pregnant?
If the prescriber and patient decide against continuing Taltz, the alternative strategy typically depends on the underlying condition being treated. Other systemic therapies may be considered, but safety varies by medication and trimester, so the choice is usually condition-specific.
If you’re on Taltz and become pregnant, what should you do now?
Contact your prescribing clinician promptly to review the plan for pregnancy and to avoid uncontrolled disease. You can also ask whether your use should be reported to pregnancy safety monitoring programs (where available), since this helps build the evidence base.
---
If you share whether you’re using Taltz for psoriasis or psoriatic arthritis (and what week of pregnancy you’re in), I can narrow the safety discussion to the most relevant clinical decision points.